Feedback    Advertise    Submit Papers    Reprints    About    Help    Contact   
Upstream Processing Downstream Processing Manufacturing Analytical Facilities
Archive by Issue Archive by Article Type Supplements
CMC Forum Press Releases
An Update on the Advantages of Fibra-Cel® Disks for Cell Culture
Julia Cino, Rich Mirro, Suzy Kedzierski
BioProcess International, Vol. 9, No. 7, August 2011, pp. 132–134
 
Other Benefits

Because higher yields are possible, smaller bioreactors can be used to substantially reduce the initial capital expenditure as well as reduce the utilities required for operation (such as electricity, water, and steam if required). In addition, because the cells remain entrapped, the packed bed eliminates the need for cell filtration to separate cells from the end product, thus simplifying harvesting. Last, product recovery and downstream processing can be more easily controlled because users can determine the volume of harvest material that is to be processed at any given time.

Commercial Production

Bioreactors using Fibra-Cel have been used in the production of a variety of commercial products. One example is Gendicine®, the world's first licensed gene therapeutic drug, which was developed in China by Shenzhen SiBiono Genetech Co., Ltd (Shenzhen, China). Gendicine is an anticancer treatment used to treat head and neck squamous cell carcinoma (HNSCC). Specifically Gendicine is a replication-incompetent, recombinant human adenovirus engineered to contain the human wild-type p53 tumor-suppressor gene and is produced by the SBN-Cel cell line, which was subcloned from the human embryonic kidney (HEK) cell line 293. After scaling up the process from roller bottles, New Brunswick's bioreactor with Fibra-Cel technology was selected over a competitor's system because it produced 15× greater yields of viral particles (5).

Other examples of commercial production include end products such as EPO, which can now be commercially produced on the bench using Fibra-Cel technology, eliminating the need for labor-intensive and space-consuming roller bottles. A substantial portion of the world's human rabies vaccine is also produced using New Brunswick's Fibra-Cel technology. Additionally, many of our customers are currently using Fibra-Cel in their proprietary processes to produce interferons, diagnostic test kits, monoclonal antibodies, and hormones.

In summary, Fibra-Cel provides benefits in research laboratories as well as in commercial production. Our customers have found that because yields are high, bioreactors containing Fibra-Cel packed beds can outperform much larger-sized bioreactors, thereby achieving commercial-scale production in a bioreactor with a far smaller footprint. Production space requirements are reduced, as are costs associated with labor, start-up, and operations.

Trademarks: Fibra-Cel® is a registered trademark owned by Celite Corporation and licensed to New Brunswick Scientific Co., Inc. USA. CelliGen® is a registered trademark of New Brunswick Scientific Co., Inc. USA. The New Brunswick Logo™, and the New Brunswick Logo with Flask design are pending trademarks of Eppendorf AG (Germany). Gendicine® is a registered trademark of Shenzhen SiBiono GeneTech Co., Ltd (China).

Author Details
Julia Cino, PhD, is research and development manager; Rich Mirro is executive director of bioprocessing portfolio management; and Suzy Kedzierski is marketing communications manager for New Brunswick Scientific, PO Box 4005, Edison NJ; bioinfo@nbsc.comwww.nbsc.com.

REFERENCES
1.) Langer, ES. 2010–2011. Perfusion Bioreactors Are Making a Comeback but Industry Misconceptions Persist. Bioprocessing J. Winter 9:49-52.

2.) Feng, Q. 2006. Expansion of Engrafting Human Hematopoietic Stem/Progenitor Cells in Three-Dimensional Scaffolds with Surface-Immobilized Fibronectin. J. Biomed. Mater. Res. A 78:781-791.

3.) Meuwly, F.. 2006.Packed-Bed Bioreactors for Mammalian Cell Culture: Bioprocess and Biomedical Applications, Elsevier Inc.:46-56.

4.) Hassanzadeh, S. 2011. High Vero Cell Density and Rabies Proliferation on Fibra-Cel Disks Versus Cytodex-1 in Spinner Flask. Pakistan J. Biol. Sci.:1-8.

5.) Peng, Z. 2004.The Genesis of Gendicine: The Story Behind the First Gene TherapyBioPharm Int.

 «PREVIOUS PAGE    1  |    2   |  
 
| | Share
The 2014 BioProcess International Awards
Nominations are now open for the 2014 BioProcess International Awards. The 2014 awards recognize and honor the individuals, organizations and technologies that most significantly impacted and advanced biotherapeutic development and manufacturing.

The winners will be announced at our awards ceremony during the BioProcess International Conference & Exhibition in Boston, October 22, 2014.

Submit your nominations today!




Biotherapeutic Formulation and Delivery
Webinars   
Subscribe   
Reprints   
Contact   
About   
Informa plc
©2002 - 2009 BioProcess International
Ph: 508-616-5550

In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer.

By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way BioProcess International uses cookies please go to our Cookie Policy page.